<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866590</url>
  </required_header>
  <id_info>
    <org_study_id>PIECE 01-2019</org_study_id>
    <nct_id>NCT03866590</nct_id>
  </id_info>
  <brief_title>Pyruvate Kinase Deficiency Epidemiological Study (PIECE)</brief_title>
  <acronym>PIECE</acronym>
  <official_title>Pyruvate Kinase Deficiency Epidemiological Study. An International, Multicentre, Epidemiological Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing
      hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main
      goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit
      chronic anaemia and/or splenomegaly and/or judiance and/or hyperbilirubinemia and/or history
      of prolonged neonatal jaundice and/ or cholelithiasis of undetermined aetiology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pyruvate kinase deficiency is the most common red cell glycolytic enzyme defect causing
      hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. PKLR
      encodes a pyruvate kinase that catalyzes the transphosphorylation of phosphoenolpyruvate into
      pyruvate and ATP. The current treatment options are red cell transfusions, chelation and
      splenectomy.

      This is an international, multicentre, epidemiological and observational study.

      The patients fulfilling the inclusion criteria will be enrolled into the Study and
      genetically tested for PKLR mutations via Next generation sequencing (NGS). Any mutation
      being detected by NGS, will be confirmed by Sanger sequencing.

      PKLR-positive samples (homozygous or compound heterozygous for pathogenic variants) will be
      analysed for the identification of potential biomarkers via liquid chromatography multiple
      reaction-monitoring mass spectrometry (LC/MRM-MS) and compared to a merged control samples in
      order establish a PKD specific biomarker.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of 100 PKLR positive participants out of a cohort of 16,000 PK deficiency-suspected cases</measure>
    <time_frame>24 months</time_frame>
    <description>Number of identified pyruvate kinase deficiency patients, which showing a mutation/pathogenic variant in their PKLR gene, within a cohort of 16.000 suspected cases via using respective patients' dry blood sample for confirmatory testing (next generation sequencing of PKLR gene)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker/s establishment in PKLR-positive cohort</measure>
    <time_frame>24 months</time_frame>
    <description>The quantitative determination of small molecules within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry, and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Pyruvate Kinase Deficiency</condition>
  <arm_group>
    <arm_group_label>Patients being at risk for Pyruvate Kinase Deficiency</arm_group_label>
    <description>Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 5 years and younger than 30 years old, with high suspicion of PK
        deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined
        aetiology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Informed consent is obtained from the participant or legal representative

          -  The participant is equal or older than 5 years or equal or younger than 30 years old

          -  The participant exhibits the following symptoms of no obvious etiology:

          -  chronic anaemia and/or

          -  splenomegaly and/or

          -  jaundice and/or

          -  cholelithiasis and/or

          -  cholecystitis and/or

          -  hyperbilirubinemia and/or

          -  history of prolonged neonatal jaundice

          -  The participant is clinically diagnosed with PK deficiency

        EXCLUSION CRITERIA:

          -  Inability to provide informed consent

          -  The participant does not suffer from chronic anaemia and splenomegaly and jaundice and
             cholelithiasis and cholecystitis and hyperbilirubinemia and history of prolonged
             neonatal jaundice

          -  The etiology of chronic anaemia or splenomegaly or jaundice or cholelithiasis or
             cholecystitis or kernicterus is clearly determined and is not due to PK deficiency

          -  The participant is younger than 5 years or older than 30 years old

          -  Previously enrolled in the PIECE Study

          -  Participant in custody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <phone_ext>594</phone_ext>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanaa Gaber, PhD</last_name>
    <phone>+49 (0)38180113633</phone>
    <email>hanaa.gaber@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intervent Clinical Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Montes, MD</last_name>
      <phone>954-507-6627</phone>
      <email>Dmontes9050@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Diego Montes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood. 2000 Jun 1;95(11):3585-8.</citation>
    <PMID>10828047</PMID>
  </reference>
  <reference>
    <citation>Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D, Al-Sayegh H, London WB, Gallagher PG, Zanella A, Barcellini W. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018 May 17;131(20):2183-2192. doi: 10.1182/blood-2017-10-810796. Epub 2018 Mar 16.</citation>
    <PMID>29549173</PMID>
  </reference>
  <reference>
    <citation>Carey PJ, Chandler J, Hendrick A, Reid MM, Saunders PW, Tinegate H, Taylor PR, West N. Prevalence of pyruvate kinase deficiency in northern European population in the north of England. Northern Region Haematologists Group. Blood. 2000 Dec 1;96(12):4005-6.</citation>
    <PMID>11186276</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyruvate Kinase Deficiency</keyword>
  <keyword>Chronic anaemia</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic, Congenital Nonspherocytic</mesh_term>
    <mesh_term>Pyruvate Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The plan will be defined at a later stages</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

